Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 145

1.

Emerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimod.

Jander S, Turowski B, Kieseier BC, Hartung HP.

Mult Scler. 2012 Nov;18(11):1650-2. doi: 10.1177/1352458512463768.

PMID:
23100527
2.

Switching therapy from natalizumab to fingolimod in relapsing-remitting multiple sclerosis: clinical and magnetic resonance imaging findings.

Rinaldi F, Seppi D, Calabrese M, Perini P, Gallo P.

Mult Scler. 2012 Nov;18(11):1640-3. doi: 10.1177/1352458512464282.

PMID:
23100526
3.

Severe multiple sclerosis reactivation under fingolimod 3 months after natalizumab withdrawal.

Daelman L, Maitrot A, Maarouf A, Chaunu MP, Papeix C, Tourbah A.

Mult Scler. 2012 Nov;18(11):1647-9. doi: 10.1177/1352458512458009. Epub 2012 Aug 20.

PMID:
22907938
4.

Time to talk about timing--when to start, stop and change anti-migratory drugs in MS.

Stüve O, Hemmer B.

Mult Scler. 2012 Nov;18(11):1514-6. doi: 10.1177/1352458512464283. No abstract available.

PMID:
23100520
5.

Early switch to fingolimod may decrease the risk of disease recurrence after natalizumab interruption.

Laroni A, Brogi D, Milesi V, Abate L, Uccelli A, Mancardi G.

Mult Scler. 2013 Aug;19(9):1236-7. doi: 10.1177/1352458512468498. Epub 2012 Nov 26. No abstract available.

PMID:
23184503
6.

Switching from natalizumab to fingolimod in multiple sclerosis: a French prospective study.

Cohen M, Maillart E, Tourbah A, De Sèze J, Vukusic S, Brassat D, Anne O, Wiertlewski S, Camu W, Courtois S, Ruet A, Debouverie M, Le Page E, Casez O, Heinzlef O, Stankoff B, Bourre B, Castelnovo G, Rico A, Berger E, Camdessanche JP, Defer G, Clavelou P, Al Khedr A, Zephir H, Fromont A, Papeix C, Brochet B, Pelletier J, Lebrun C; Club Francophone de la Sclérose en Plaques Investigators.

JAMA Neurol. 2014 Apr;71(4):436-41. doi: 10.1001/jamaneurol.2013.6240.

PMID:
24566807
7.

Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS.

Kappos L, Radue EW, Comi G, Montalban X, Butzkueven H, Wiendl H, Giovannoni G, Hartung HP, Derfuss T, Naegelin Y, Sprenger T, Mueller-Lenke N, Griffiths S, von Rosenstiel P, Gottschalk R, Zhang Y, Dahlke F, Tomic D; TOFINGO study group.

Neurology. 2015 Jul 7;85(1):29-39. doi: 10.1212/WNL.0000000000001706. Epub 2015 May 29.

8.

Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis.

Kalincik T, Horakova D, Spelman T, Jokubaitis V, Trojano M, Lugaresi A, Izquierdo G, Rozsa C, Grammond P, Alroughani R, Duquette P, Girard M, Pucci E, Lechner-Scott J, Slee M, Fernandez-Bolanos R, Grand'Maison F, Hupperts R, Verheul F, Hodgkinson S, Oreja-Guevara C, Spitaleri D, Barnett M, Terzi M, Bergamaschi R, McCombe P, Sanchez-Menoyo J, Simo M, Csepany T, Rum G, Boz C, Havrdova E, Butzkueven H; MSBase Study Group.

Ann Neurol. 2015 Mar;77(3):425-35. doi: 10.1002/ana.24339. Epub 2015 Jan 17.

PMID:
25546031
9.

Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis.

Havla J, Tackenberg B, Hellwig K, Meinl I, Krumbholz M, Seitz F, Eienbröker C, Gold R, Hohlfeld R, Kleiter I, Kümpfel T.

J Neurol. 2013 May;260(5):1382-7. doi: 10.1007/s00415-012-6808-8. Epub 2012 Dec 25.

PMID:
23266894
10.

Withdrawal of fingolimod treatment for relapsing-remitting multiple sclerosis: report of six cases.

Hakiki B, Portaccio E, Giannini M, Razzolini L, Pastò L, Amato MP.

Mult Scler. 2012 Nov;18(11):1636-9. doi: 10.1177/1352458512454773. Epub 2012 Jul 24.

PMID:
22829326
11.

Switching from natalizumab to fingolimod: an observational study.

Sempere AP, Martín-Medina P, Berenguer-Ruiz L, Pérez-Carmona N, Sanchez-Perez R, Polache-Vengud J, Feliu-Rey E.

Acta Neurol Scand. 2013 Aug;128(2):e6-e10. doi: 10.1111/ane.12082. Epub 2013 Jan 22.

PMID:
23336398
12.

Reduction of the washout time between natalizumab and fingolimod.

de Seze J, Ongagna JC, Collongues N, Zaenker C, Courtois S, Fleury M, Benoilid A, Chanson JB, Blanc F; Alsacep Network.

Mult Scler. 2013 Aug;19(9):1248. doi: 10.1177/1352458513490551. Epub 2013 May 30. No abstract available.

PMID:
23722322
13.

Are natalizumab and fingolimod analogous second-line options for the treatment of relapsing-remitting multiple sclerosis? A clinical practice observational study.

Gajofatto A, Bianchi MR, Deotto L, Benedetti MD.

Eur Neurol. 2014;72(3-4):173-80. doi: 10.1159/000361044. Epub 2014 Sep 6.

PMID:
25226868
14.

Healthcare resource use and relapses with fingolimod versus natalizumab for treating multiple sclerosis: a retrospective US claims database analysis.

Bergvall N, Lahoz R, Reynolds T, Korn JR.

Curr Med Res Opin. 2014 Aug;30(8):1461-71. doi: 10.1185/03007995.2014.915802. Epub 2014 May 2.

PMID:
24754349
15.

Cost-effectiveness of natalizumab versus fingolimod for the treatment of relapsing multiple sclerosis.

O'Day K, Meyer K, Miller RM, Agarwal S, Franklin M.

J Med Econ. 2011;14(5):617-27. doi: 10.3111/13696998.2011.602444. Epub 2011 Jul 22.

PMID:
21777161
16.

Moving to fingolimod from natalizumab in multiple sclerosis-reply.

Cohen M, Lebrun C.

JAMA Neurol. 2014 Jul 1;71(7):925. doi: 10.1001/jamaneurol.2014.1138. No abstract available.

PMID:
25023556
17.

Multiple sclerosis: Natalizumab to fingolimod--the washout whitewash.

Stangel M, Stüve O.

Nat Rev Neurol. 2014 Jun;10(6):311-3. doi: 10.1038/nrneurol.2014.82. Epub 2014 May 20. No abstract available.

PMID:
24840971
18.

Fingolimod after natalizumab and the risk of short-term relapse.

Jokubaitis VG, Li V, Kalincik T, Izquierdo G, Hodgkinson S, Alroughani R, Lechner-Scott J, Lugaresi A, Duquette P, Girard M, Barnett M, Grand'Maison F, Trojano M, Slee M, Giuliani G, Shaw C, Boz C, Spitaleri DL, Verheul F, Haartsen J, Liew D, Butzkueven H; MSBase Study Group.

Neurology. 2014 Apr 8;82(14):1204-11. doi: 10.1212/WNL.0000000000000283. Epub 2014 Mar 7.

19.

Moving to fingolimod from natalizumab in multiple sclerosis: the ENIGM is not solved.

Bianco A, Rossini PM, Mirabella M.

JAMA Neurol. 2014 Jul 1;71(7):924-5. doi: 10.1001/jamaneurol.2014.1135. No abstract available.

PMID:
25023553
20.

Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis.

Radue EW, O'Connor P, Polman CH, Hohlfeld R, Calabresi P, Selmaj K, Mueller-Lenke N, Agoropoulou C, Holdbrook F, de Vera A, Zhang-Auberson L, Francis G, Burtin P, Kappos L; FTY720 Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) Study Group.

Arch Neurol. 2012 Oct;69(10):1259-69.

PMID:
22751847
Items per page

Supplemental Content

Write to the Help Desk